Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media
* Exclusive license grants Vertex one clinical and one pre-clinical DNA-PK inhibitor for use in gene-editing applications in six specific genetic disease areas
* Merck retains the rights to both compounds in all other disease areas, including oncology
* Merck retains the rights to utilize and license this technology in
gene editing outside of the six specified disease areas
Merck, a leading science and technology company, today announced!-->…